|
Affiliation |
Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Pediatrics |
|
Title |
Professor |
|
External Link |
|
MORITAKE Hiroshi
|
|
|
Research Areas 【 display / non-display 】
-
Life Science / Embryonic medicine and pediatrics
-
Life Science / Hematology and medical oncology
Papers 【 display / non-display 】
-
Ultrasound-Guided Supraclavicular Approach to the Brachiocephalic Vein Cannulation in Pediatric Patients With Hematological and Oncological Diseases Reviewed
Nakame Kazuhiko, Masuya Ryuta, Nakazawa Shun, Nakagawa Midori, Yamada Ai, Kinoshita Mariko, Kamimura Sachiyo, Moritake Hiroshi, Ieiri Satoshi, Nanashima Atushi
Journal of the Japanese Society of Pediatric Surgeons 60 ( 2 ) 158 - 165 2024.4
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Pediatric Surgeons
<i>Purpose</i>: Central venous catheters (CVCs) are used in the treatment of pediatric hematological and oncological diseases. Recently, the ultrasound (US)-guided supraclavicular approach to brachiocephalic vein cannulation with in-plane views has been described as a safe central venous catheterization technique.<i>Methods</i>: A retrospective study was performed on patients who underwent US-guided tunneled CVC insertion into the internal jugular vein with out-of-plane views (IJV group) and the brachiocephalic vein with in-plane views (BCV group). The patients’ background characteristics, surgical outcomes, and complications were compared retrospectively.<i>Results</i>: A total of 40 tunneled CVCs (IJV group: n = 15, BCV group: n = 25) were inserted in 34 patients. The patients’ background characteristics were not significantly different between the two groups. The operative times were 30 min (range: 27–33 min) in the IJV group and 25.8 min (range: 22–27 min) in the BCV group. The BCV group had a significantly shorter operative time (p = 0.0026). Intraoperative complications were observed in one patient (6.7%) in the IJV group and none of the patients in the BCV group. Complications during maintenance were observed in 10 patients (66.7%) in the IJV group and 17 patients (68%) in the BCV group. Catheter-related bloodstream infection was noted in 10 patients (66.7%) in the IJV group and 12 patients (52%) in the BCV group; these infection rates were not significantly different. The periods of CVC implantation were 273 days (172–363.5 days) in the IJV group and 152 days (101–280 days) in the BCV group, which were not significantly different.<i>Conclusions</i>: A real-time US-guided supraclavicular approach to brachiocephalic catheterization was considered a safe technique for pediatric patients with hematological and oncological diseases.
-
Matsumoto F, Yokogami K, Yamada A, Moritake H, Watanabe T, Yamashita S, Sato Y, Takeshima H
Human cell 37 ( 2 ) 523 - 530 2024.2
Language：English Publishing type：Research paper (scientific journal) Publisher：Human Cell
Atypical teratoid/rhabdoid (AT/RT) is a rare and highly malignant tumor of the central nervous system (CNS). It is most commonly found in children less than 5 years of age and is associated with inactivation of loss of function of SMARCB1/INI1. An experimental model for AT/RT is necessary to develop new and effective therapies. We established a patient-derived new cell line (MZ611ATRT), which showed loss of BAF-47. MZ611ATRT genetically features somatic heterozygous deletion of SMARCB1 and single nucleotide deletion of the residual allele, exon 5 ([c.541delC]), resulting in a stop codon at codon 954 by frameshift. We assessed the RNA-sequencing data of the other two AT/RT cell lines with forced expression of SMARCB1 available from public databases. We found SMARCB1 overexpression significantly down-regulates the expression of a group of enzymes related to cholesterol biosynthesis. Simvastatin was highly sensitive against MZ611ATRT cells and induced apoptosis (IC50 was 3.098 µM for MZ611ATRT, 41.88uM for U-87 MG, 23.34uM for IOMM-Lee, and 18.12uM for U-251 MG.). Pathways involved in cholesterol biosynthesis may be new targets for adjuvant therapy of AT/RT.
-
B-cell deficiency identified by newborn screening Reviewed
Matsumoto Takayuki, Nishimura Toyoki, Yamamoto Ayako, Sawada Hirotake, Moritake Hiroshi
JSIAD Journal 3 ( 1 ) 16 - 20 2024.2
Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Japanese Society for Immunodeficiency and Autoinflammatory Diseases
Newborn screening（NBS）is carried out at public expense for approximately 20 diseases in Japan; however, each prefecture independently conducts additional NBS including several more diseases. Miyazaki Prefecture has optionally included inborn errors of immunity（IEIs）and lysosomal storage diseases since April 2020. We herein report a baby who suffered from B-cell deficiency（BCD）that was identified by NBS conducted in Miyazaki Prefecture. The baby had low levels of kappa-deleting recombination excision circles（KRECs）and was referred to our hospital. Several measurements of CD19-positive B cells in the peripheral blood consistently showed values <2%, leading to the diagnosis of BCD. Periodic immunoglobulin replacement successfully led to a healthy outcome without serious infection developing over a period of more than 17 months. This is the first case of BCD identified by NBS and that underwent prophylactic gamma globulin replacement in Japan. Severe combined immunodeficiency disease and BCD are IEIs known to cause severe sequelae, and patients sometimes die without a correct diagnosis being made; therefore, their early diagnosis and early treatment are extremely important. The inclusion of IEIs in NBS has proven to be cost-effective all over the world. In the future, it is expected that IEIs will be covered by NBS public funds in Japan as well.
-
Ishimura M., Eguchi K., Sonoda M., Tanaka T., Shiraishi A., Sakai Y., Yasumi T., Miyamoto T., Voskoboinik I., Hashimoto K., Matsumoto S., Ozono S., Moritake H., Takada H., Ohga S.
International Journal of Hematology 119 ( 5 ) 592 - 602 2024
Language：English Publishing type：Research paper (scientific journal) Publisher：International Journal of Hematology
Familial hemophagocytic lymphohistiocytosis (FHLH) is a fatal hyperinflammation syndrome arising from the genetic defect of perforin-mediated cytolysis. Curative hematopoietic cell transplantation (HCT) is needed before development of central nervous system (CNS) disease. We studied treatment outcomes of 13 patients (FHLH2 n = 11, FHLH3 n = 2) consecutively diagnosed from 2011 to 2022 by flow cytometric screening for non-myeloablative HCT in a regional treatment network in Kyushu, Japan. One patient with a novel PRF1 variant escaped screening, but all patients with FHLH2 reached diagnosis and 8 of them received HCT until 3 and 9 months of age, respectively. The earliest HCT was conducted 65 days after birth. Three pretransplant deaths occurred in newborns with liver failure at diagnosis. Ten posttransplant patients have remained disease-free, 7 of whom had no neurological involvement. Time from first etoposide infusion to HCT was shorter in patients without CNS disease or bleeding than in patients with those factors (median [range] days: 62 [50–81] vs. 122 [89–209], p = 0.016). Six of 9 unrelated patients had a PRF1 c.1090_1091delCT variant. These results suggest that the critical times to start etoposide and HCT are within 3 months after birth and during etoposide control, respectively. Newborn screening may increase the percentage of disease-free survivors without complications.
-
Novel splice site variant of TMEM38B in osteogenesis imperfecta type XIV Reviewed
Kodama Y., Meiri S., Asada T., Matsuyama M., Makino S., Iwai M., Yamaguchi M., Moritake H.
Human Genome Variation 10 ( 1 ) 25 2023.12
Language：English Publishing type：Research paper (scientific journal) Publisher：Human Genome Variation
Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by brittle bones. In this case report, we describe a patient who suffered from OI type XIV with a novel splice site variant in the TMEM38B gene. Further research is needed to better understand the relationship between the phenotype of OI type XIV and this variant.
Books 【 display / non-display 】
-
今日の治療指針
盛武 浩（ Role： Joint author , 小児の白血病）
医学書院 2021 （ ISBN:978-4-260-04283-3 ）
Responsible for pages：1494-1495 Language：Japanese Book type：Textbook, survey, introduction
-
血液専門医テキスト 改訂第3版
盛武 浩（ Role： Joint author , 小児の急性骨髄性白血病）
南江堂 2019
Responsible for pages：456-460 Language：Japanese Book type：Textbook, survey, introduction
-
鉄欠乏性貧血. 小児疾患診療のための病態生理3 改訂第5版.
盛武 浩（ Role： Sole author）
東京医学社 2016
Language：Japanese Book type：Textbook, survey, introduction
-
白血球と分画
盛武 浩（ Role： Sole author）
今日の小児診断指針 2004.7
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia Reviewed
Iyoda S., Yoshida K., Shoji K., Ito N., Tanaka M., Nannya Y., Yamato G., Tsujimoto S., Shiba N., Hayashi Y., Shiozawa Y., Shiraishi Y., Chiba K., Okada A., Tanaka H., Miyano S., Koga Y., Goto H., Moritake H., Terui K., Ito E., Kiyokawa N., Tomizawa D., Taga T., Tawa A., Takita J., Nishikori M., Adachi S., Ogawa S., Matsuo H.
Leukemia 2024
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Leukemia
-
Reduced-intensity therapy for relapsed Philadelphia chromosome-positive leukemia Reviewed
Nagasawa S., Yamada A., Nakagawa M., Kinoshita M., Koga Y., Ohga S., Moritake H.
Pediatric Blood and Cancer 71 ( 2 ) e30802 2023
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Pediatric Blood and Cancer
DOI： 10.1002/pbc.30802
-
Nagasawa S., Yamada A., Kinoshita M., Kamimura S., Moritake H.
Pediatrics International 64 ( 1 ) e14970 2022.1
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Pediatrics International
DOI： 10.1111/ped.14970
-
Kinoshita M., Yamada A., Saito Y., Kamimura S., Moritake H.
Pediatrics International 64 ( 1 ) e14975 2022.1
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Pediatrics International
DOI： 10.1111/ped.14975
-
Taga T., Tanaka S., Hasegawa D., Terui K., Toki T., Iwamoto S., Hiramatsu H., Miyamura T., Hashii Y., Moritake H., Nakayama H., Takahashi H., Shimada A., Taki T., Ito E., Hama A., Ito M., Koh K., Hasegawa D., Saito A.M., Adachi S., Tomizawa D.
Leukemia 35 ( 12 ) 3622 - 3624 2021.12
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Leukemia
Following the publication of this article, the authors noted an error in the data reported.
Presentations 【 display / non-display 】
-
COVID-19 ワクチン接種後に発症した心膜心筋炎
二見 加菜、髙村 一成、山下 尚人、原田 雅子、澤 大介、盛武 浩
第91回日本小児科学会宮崎地方会, 宮崎
Event date： 2022.3.20
Presentation type：Oral presentation (general)
-
発症早期に免疫修飾治療を開始したラスムッセン脳炎
山本 夏穂、 下田 貴史、 森 こずえ、 前田 謙一、 木許 恭宏、 池田 俊郎、 盛武 浩
第91回日本小児科学会宮崎地方会, 宮崎
Event date： 2022.3.20
Presentation type：Oral presentation (general)
-
集団健診を契機に診断された頻拍誘発性心筋症２例
興梠 智子、髙村 一成、山下 尚人、原田 雅子、盛武 浩
第91回日本小児科学会宮崎地方会, 宮崎
Event date： 2022.3.20
Presentation type：Oral presentation (general)
-
Clonal architecture and its prognostic significance in KMT2A-rearranged acute myeloid leukemia
Matsuo H, Yoshida K, Nannya Y, Kamikubo Y, Saito S, Koga Y, Moritake H, Terui K, Kawaguchi K, Okamoto Y,Nakayama H, Kanno M, Hino M, Akane Y, Inoue A, Shimada A, Goto H, Ueno H, Takita J, Yamato G, Shiba N, Hayashi Y, Shiraishi Y, Miyano S, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Ogawa S, Adachi S
Event date： 2021.9.23 - 2021.9.25
Presentation type：Oral presentation (general)
-
不明熱を呈し, リンパ節生検により診断に至ったTAFRO症候群の１例
小川 智香, 山元 綾子, 西村 豊樹, 盛武 浩
第90回日本小児科学会宮崎地方会, 宮崎
Event date： 2021.9.12
Presentation type：Oral presentation (general)
Awards 【 display / non-display 】
-
日本白血病研究基金 一般研究賞（クレディセゾン賞）
2014.11 公益信託 日本白血病研究基金助成事業
盛武 浩
Award type：Award from publisher, newspaper, foundation, etc. Country：Japan
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
PDXマウスモデルを用いた再発難治小児急性骨髄性白血病の病態解明と新規治療法開発
Grant number：23K07337 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究（C）
Authorship：Principal investigator
-
Mfsd2遺伝子KOマウスを用いた、脳内ＤＨＡによるエネルギー代謝調節機構の解明
2018.04
科学研究費補助金 基盤研究(C)
KOマウスの脳の組織学的評価と、摂食行動およびエネルギー代謝特性、代謝関連遺伝子発現を評価する。
-
網羅的遺伝子解析をとおして同定した家族性白血病原因遺伝子の機能解析
2016.04 - 2019.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
網羅的遺伝子解析をとおして同定した家族性白血病原因遺伝子と想定される2つの遺伝子変異の機能解析を行う
-
家族性急性リンパ性白血病の原因遺伝子の探索
2013.04 - 2016.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
家族性急性リンパ性白血病の原因遺伝子の探索
-
Mfsd2遺伝子ノックアウトマウスにおけるエネルギー代謝特性の解明
2013.04 - 2015.03
科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)
我々が作成したMfsd2遺伝子ノックアウトマウスにおけるエネルギー代謝特性を解析する